Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate HUTCHMED (China) Limited before investing.

In this article, we go over a few key elements for understanding HUTCHMED (China) Limited’s stock price such as:

• HUTCHMED (China) Limited’s current stock price and volume
• Why HUTCHMED (China) Limited’s stock price changed recently
• Upgrades and downgrades for HCM from analysts
• HCM’s stock price momentum as measured by its relative strength

About HUTCHMED (China) Limited (HCM)

Before we jump into HUTCHMED (China) Limited’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Want to learn more about HUTCHMED (China) Limited’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about HUTCHMED (China) Limited.

HUTCHMED (China) Limited’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, HUTCHMED (China) Limited’s stock price was $11.130.

HUTCHMED (China) Limited is up 3.34% from its previous closing price of $10.770.

During the last market session, HUTCHMED (China) Limited’s stock traded between $10.905 and $11.130. Currently, there are approximately 859.51 million shares outstanding for HUTCHMED (China) Limited.

HUTCHMED (China) Limited’s price-earnings (P/E) ratio is currently at 20.7, which is high compared to the Pharmaceuticals industry median of 20.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

HUTCHMED (China) Limited Stock Price History

HUTCHMED (China) Limited’s (HCM) price is currently up 3.44% so far this month.

During the month of July, HUTCHMED (China) Limited’s stock price has reached a high of $11.810 and a low of $10.620.

Over the last year, HUTCHMED (China) Limited has hit prices as high as $18.300 and as low as $9.770. Year to date, HUTCHMED (China) Limited’s stock is down 16.5%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused HUTCHMED (China) Limited Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there were analysts who downgraded HUTCHMED (China) Limited’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate HUTCHMED (China) Limited’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on HUTCHMED (China) Limited’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

HUTCHMED (China) Limited’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about HUTCHMED (China) Limited (HCM) by visiting AAII Stock Evaluator.

Relative Price Strength of HUTCHMED (China) Limited

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, HUTCHMED (China) Limited has a weighted four-quarter relative price strength of -16.50%, which translates to a Momentum Score of 15 and is considered to be Very Weak.

Want to learn more about how HUTCHMED (China) Limited is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

HUTCHMED (China) Limited Stock Price: Bottom Line

As of July 31, 2026, HUTCHMED (China) Limited’s stock price is $11.130, which is up 3.34% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like HUTCHMED (China) Limited stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.